Invention Grant
- Patent Title: Use of NK-1 receptor antagonist serlopitant in pruritus
-
Application No.: US15956102Application Date: 2018-04-18
-
Publication No.: US10278953B2Publication Date: 2019-05-07
- Inventor: Xiaoming Zhang , Edward F. Schnipper , Andrew J. Perlman , James W. Larrick
- Applicant: Menlo Therapeutics Inc.
- Applicant Address: US CA Redwood
- Assignee: Menlo Therapeutics Inc.
- Current Assignee: Menlo Therapeutics Inc.
- Current Assignee Address: US CA Redwood
- Agency: Morrison & Foerster LLP
- Main IPC: A61K31/403
- IPC: A61K31/403 ; A61K9/48 ; A61K9/20 ; A61K45/06 ; A61K9/00 ; A61K31/4035 ; A61K47/10 ; A61K9/06
Abstract:
The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
Public/Granted literature
- US20180325867A1 USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS Public/Granted day:2018-11-15
Information query
